0 Replies
... With shire pharmaceuticals Extensive patent prosecution and litigation experience Broad scientific background donna falcetti, mba, director of investor relations Served as product manager of rnai ... Contine Reading & Discuss→
0 Replies
BOULDER, CO, June 9, 2009—miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA-based therapeutics for cardiovascular and muscle disease, today announced that its Chief Scientific Advisor and Co-Founder, Eric N. Olson, Ph.D., has been named the winner of the prestigious Grand Prize of the... Contine Reading & Discuss→
0 Replies
Copenhagen, Denmark, June 4, 2009 Santaris Pharma today announced that the cancer drug EZN-2968 – an inhibitor of HIF-1alpha, jointly developed by Enzon Pharmaceuticals and Santaris Pharma A/S – was well tolerated and showed early signs of clinical benefit in previously treated cancer patients with advanced malignancies. EZN-2968 is being evaluated... Contine Reading & Discuss→
0 Replies
Copenhagen, Denmark, June 3, 2009 Santaris Pharma and Copenhagen Institute of Technology, Aalborg University, Denmark, announced today that Director of microRNA, Santaris Pharma, Sakari Kauppinen, has been appointed Adjunct Professor in RNA Biology at Copenhagen Institute of Technology. The appointment has immediate effect and will last five years. Sakari Kauppinen, who... Contine Reading & Discuss→
0 Replies
København, 3. juni, 2009 Santaris Pharma og Aalborg Universitet (Copenhagen Institute of Technology) meddeler at director for microRNA, Santaris Pharma, Sakari Kauppinen, er blevet udnævnt til adjungeret professor i RNA biologi på Aalborg Universitet, København. Udnævnelsen har umiddelbar effekt og vil vare fem år. Sakari Kauppinen, som fortsætter i sin nuværende... Contine Reading & Discuss→
0 Replies
BOULDER, CO, June 2, 2009—miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA (miRNA) based therapeutics for cardiovascular and muscle disease, today announced the achievement of several key milestones resulting in the approval of the second tranche of last year’s $8 million Series A... Contine Reading & Discuss→
